Peptide Profile: VIP5 is a laboratory-grade analogue of vasoactive intestinal peptide (VIP), a 28–amino-acid neuropeptide found in the gut, brain, heart, and immune system. VIP normally relaxes smooth muscle, dilates blood vessels, increases digestive secretions, and modulates immune and inflammatory signaling. VIP5 is designed to mimic these actions for research into vascular tone, gut motility, immune regulation, and neuroinflammation. It remains an experimental peptide, not an FDA-approved drug or casual wellness supplement.

VIP5 Dosing Protocol (Educational Example Only)

This protocol is an illustrative research-style framework based on published VIP nasal and injectable ranges, adapted generically for VIP-type peptides. It is not a medical prescription. Actual dosing, if ever used clinically, must be individualized and supervised by a qualified clinician.

Phase Time frame Male dosing (example) Female dosing (example) Route & schedule Goals & monitoring
Baseline assessment 2–4 weeks before start No VIP5 yet. Full history, exam, and labs: CBC, CMP, fasting glucose/A1c, lipids, blood pressure, and review of current medications and supplements. Same as males; no sex-based adjustments at this stage. Include pregnancy test where relevant and review contraception. N/A Confirm that VIP-type therapy is appropriate for a research or supervised clinical context (e.g., inflammatory, vascular, or neuro-immune questions). Screen for uncontrolled asthma, severe hypotension, active GI bleeding, or unexplained diarrhea, which may worsen with VIP-like vasodilation and secretory effects.
Initiation Weeks 1–2 25–50 mcg VIP5 once daily, intranasal (one spray) or subcutaneous, using the lowest concentration available. Same range (25–50 mcg once daily). Female dose is not typically weight- or sex-based; clinician may start at lower end in very low-body-weight or frail patients. Once daily at the same time; alternate nostrils if intranasal, or rotate injection sites if subcutaneous. Primary aim is tolerability, not symptom change. Track blood pressure, heart rate, bowel frequency, flushing, headache, and sleep. Mild nasal irritation or transient light-headedness may appear; persistent or severe reactions should trigger dose reduction or discontinuation.
Early titration Weeks 3–4 If well tolerated, increase to 50 mcg twice daily (approx. 100 mcg/day) or a single 100 mcg dose, as directed by supervising clinician. Same escalation pattern and ceiling. Split doses (morning and late afternoon) to smooth exposure; avoid bedtime dosing in patients prone to nocturnal reflux or palpitations. Begin evaluating for desired effects (e.g., improved stamina, reduced inflammatory flares, or better GI comfort) while watching for hypotension, loose stools, or excessive flushing. Repeat basic vitals and symptom diary review at least once during this phase.
Structured escalation Weeks 5–8 Titrate toward a working range of 100–200 mcg/day, divided into 2–4 doses (for example, 50 mcg up to four times daily) if benefits plateau at lower doses and side-effects remain mild. Same total daily range; some clinicians may choose slightly slower titration in smaller or more sensitive individuals regardless of sex. Maintain a consistent schedule. For intranasal use, alternate nostrils and avoid immediately blowing the nose after dosing. For injections, use sterile technique and proper disposal. Identify the lowest effective daily dose that yields measurable benefit on targeted outcomes (e.g., inflammatory markers, exercise tolerance, cognitive clarity) without troublesome adverse effects. Labs (CMP, electrolytes) and blood pressure checks are recommended at least once per month during escalation.
Maintenance cycle Weeks 9–16 Continue at the individualized effective dose, often somewhere between 50 and 200 mcg/day in divided doses. Some research protocols explore higher totals; these should be reserved for specialized settings. Same as males; no routine sex-specific difference in maintenance dosing. Maintain stable dosing pattern; avoid frequent self-adjustments. Typical cycles run 8–12 weeks, sometimes up to 16 weeks, followed by a drug-free interval of 4–8 weeks. Reassess clinical status every 4–8 weeks: symptom scores, quality of life, bowel habits, blood pressure, and any neurological changes. If benefit wanes or side-effects increase, first attempt dose reduction, then consider cycling off. Long-term continuous use is not well studied.
Taper / off-cycle 2–4 weeks Reduce to half the maintenance dose for 1–2 weeks, then discontinue. Same approach. Either decrease dose frequency (e.g., twice daily to once daily) or lower per-dose amount before full stop. Watch for rebound of underlying symptoms or new issues such as headaches or mood changes. Use off-cycle intervals to re-evaluate whether restarting VIP5 is justified or whether alternative strategies (lifestyle, other therapies) are preferable.

Key safety notes

VIP5, like other VIP analogues, remains a research peptide with limited controlled human data. Potential adverse effects include hypotension, tachycardia, flushing, diarrhea, abdominal cramping, nasal irritation, and headaches. It must not be used in pregnancy, breastfeeding, or unsupervised self-experimentation. All peptide decisions should be made with a licensed clinician who can interpret labs, drug interactions, and long-term risk.

References

https://www.proteinpeptides.com/peptide-profiles/peptide-profile-vip5/
https://en.wikipedia.org/wiki/Vasoactive_intestinal_peptide
https://www.mdpi.com/1422-0067/21/1/65
https://www.restorativecompounding.com/blog/vip-vasoactive-intestinal-peptide-nasal-spray-guide-dosage-safety-amp-wellness-tips
https://www.strivepharmacy.com/medications/vasoactive-intestinal-peptide-vip-nasal-spray